Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy. This is an ASCO Meeting Abstract from the 2023 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results